Shares of Prothena Corporation PRTA plummeted 53.5% year to date compared with the industry’s decline of 0.6%. The recent ...

Tempus AI TEM is entering a phase of strong operating momentum, backed by significant acceleration in both revenues and gross profit. This trend became particularly clear in the company’s last two ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...